CENTRAL TRUST Co Has $1.61 Million Stock Position in The Clorox Company $CLX

CENTRAL TRUST Co lowered its position in The Clorox Company (NYSE:CLX) by 3.4% during the second quarter, HoldingsChannel.com reports. The firm owned 13,395 shares of the company’s stock after selling 478 shares during the quarter. CENTRAL TRUST Co’s holdings in Clorox were worth $1,608,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. American National Bank & Trust grew its stake in shares of Clorox by 69.5% in the 2nd quarter. American National Bank & Trust now owns 217 shares of the company’s stock valued at $26,000 after buying an additional 89 shares in the last quarter. NewSquare Capital LLC lifted its stake in Clorox by 567.6% in the second quarter. NewSquare Capital LLC now owns 227 shares of the company’s stock valued at $27,000 after acquiring an additional 193 shares during the last quarter. Hantz Financial Services Inc. acquired a new position in shares of Clorox during the 2nd quarter worth $31,000. Ransom Advisory Ltd bought a new position in shares of Clorox during the 1st quarter valued at $35,000. Finally, GW&K Investment Management LLC raised its holdings in shares of Clorox by 239.1% during the 1st quarter. GW&K Investment Management LLC now owns 295 shares of the company’s stock valued at $43,000 after purchasing an additional 208 shares in the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox Stock Down 0.3%

CLX opened at $104.70 on Thursday. The business has a 50 day moving average of $118.55 and a 200-day moving average of $124.12. The stock has a market capitalization of $12.77 billion, a price-to-earnings ratio of 16.06, a P/E/G ratio of 0.92 and a beta of 0.52. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15. The Clorox Company has a 1-year low of $104.08 and a 1-year high of $171.37.

Clorox (NYSE:CLX) last released its earnings results on Monday, November 3rd. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.78 by $0.07. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The firm had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $1.41 billion. During the same period in the prior year, the company earned $1.86 EPS. The business’s quarterly revenue was down 18.9% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. As a group, sell-side analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, November 6th. Investors of record on Wednesday, October 22nd were paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 4.7%. The ex-dividend date was Wednesday, October 22nd. Clorox’s dividend payout ratio (DPR) is presently 77.86%.

Insiders Place Their Bets

In related news, COO Eric H. Reynolds sold 15,041 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the transaction, the chief operating officer directly owned 54,221 shares in the company, valued at $6,711,475.38. The trade was a 21.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.63% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on CLX shares. JPMorgan Chase & Co. decreased their price objective on shares of Clorox from $127.00 to $120.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. UBS Group set a $119.00 price target on Clorox and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Barclays lowered their price objective on Clorox from $112.00 to $108.00 and set an “underweight” rating on the stock in a report on Tuesday, November 4th. Deutsche Bank Aktiengesellschaft reduced their target price on Clorox from $128.00 to $121.00 and set a “hold” rating for the company in a report on Tuesday, November 4th. Finally, Wells Fargo & Company decreased their target price on Clorox from $125.00 to $117.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 4th. One analyst has rated the stock with a Buy rating, twelve have assigned a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and an average price target of $125.69.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.